Amylyx Pharmaceuticals publishes presentation on Phase 3 Avexitide trial results

The presentation reported that all prespecified, multiplicity-controlled secondary endpoints were met, with hypoglycemic event reductions ranging from 42% to 63% versus placebo. Adverse events were primarily gastrointestinal or injection-site reactions and generally mild to moderate; treatment discontinuations occurred in 4% of patients receiving avexitide versus 3% with placebo. Body weight and fasting plasma glucose showed no clinically meaningful changes through Week 16.